ANNX · XBRL financial data

Annexon financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ANNX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	28	23*	21	25	30	43*	48	44	50	43*	36	47
General and administrative	7	7*	8	9	9	9*	9	8	7	8*	10	11
Total operating expenses	35	30*	29	34	39	52*	57	52	57	50*	46	57
Operating income (loss)	(35)	(30)*	(29)	(34)	(39)	(52)*	(57)	(52)	(57)	(50)*	(46)	(57)
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(32)	(28)*	(25)	(30)	(35)	(49)*	(54)	(49)	(55)	(48)*	(44)	(55)
Earnings per share, basic USD per share	(0.43)	(0.36)*	(0.21)	(0.23)	(0.25)	(0.31)*	(0.37)	(0.34)	(0.37)	(0.28)*	(0.23)	(0.28)
Earnings per share, diluted USD per share	(0.43)	(0.36)*	(0.21)	(0.23)	(0.25)	(0.31)*	(0.37)	(0.34)	(0.37)	(0.28)*	(0.23)	(0.28)
Weighted average shares, basic millions of shares	75	78*	123	130	140	157*	148	148	149	175*	194	201
Weighted average shares, diluted millions of shares	75	78*	123	130	140	157*	148	148	149	175*	194	201

Fiscal quarters (ANNX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	133	225	152	157	80	49	97	132	139	162	175	199
Marketable securities	32	35	113	211	261	263	167	95	49	76	50	10
Prepaid and other current assets	4	4	6	5	4	4	4	4	4	4	3	4
Total current assets	169	264	271	374	344	316	268	231	193	242	228	213
Property and equipment, net	15	15	14	14	13	13	12	12	11	11	10	10
Right-of-use asset	18	18	18	17	17	17	16	16	16	15	15	14
Total assets	204	298	304	406	379	350	303	265	229	278	263	246
Accounts payable	5	5	4	4	7	10	10	12	18	15	18	16
Accrued liabilities	10	10	7	11	—	—	—	—	—	—	—	—
Total current liabilities	17	18	13	17	20	31	34	41	44	43	36	38
Lease liability, non-current	30	29	29	28	27	26	26	25	24	23	22	22
Total liabilities	47	47	42	45	47	57	59	66	68	66	58	60
Accumulated deficit	(545)	(572)	(598)	(627)	(662)	(711)	(765)	(814)	(869)	(917)	(962)	(1,017)
Total stockholders' equity	157	251	262	361	332	293	244	199	161	212	205	186
Total liabilities and equity	204	298	304	406	379	350	303	265	229	278	263	246
Common shares outstanding (cover page) millions of shares	—	78	—	—	—	109	—	—	—	149	—	—

Fiscal quarters (ANNX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(32)	(28)*	(25)	(30)	(35)	(49)*	(54)	(49)	(55)	(48)*	(44)	(55)
Stock-based compensation	5*	4*	5	5*	5*	5*	5	4	4*	3*	4	5
Depreciation and amortization	1*	1*	1	1*	1*	1*	1	1*	1*	1*	1	1*
Net cash from operating activities	(28)*	(23)*	(28)	(22)*	(32)*	(36)*	(50)	(38)*	(52)*	(46)*	(47)	(48)*
Purchases of property and equipment	0*	0*	—	—	—	0*	0	0*	0*	0*	0	0*
Net cash from investing activities	48*	(2)*	(77)	(97)*	(46)*	1*	98	73*	46*	(27)*	27	40*
Proceeds from issuing common stock	0*	0*	33	7*	0*	5*	0	0*	14*	14*	34	32*
Net cash from financing activities	0*	118*	32	124*	0*	5*	0	0*	14*	95*	33	32*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Annexon	199	not reported	(48)*	not reported	4.4 quarters	Q2 FY26 10-QJun 30, 2026
DBV Technologies	166	1.6	(52)*	314.4M	3.2 quarters	Q3 FY26 10-QSep 30, 2026
Corvus Pharmaceuticals	19	not reported	(15)*	84.1M	14.0 quarters	Q2 FY26 10-QJun 30, 2026
Verastem	136	40	(44)*	90.6M	3.1 quarters	Q2 FY26 10-QJun 30, 2026
Heron Therapeutics	21	not reported	(2.2)*	189.9M	19.3 quarters	Q2 FY26 10-QJun 30, 2026
Aldeyra Therapeutics	45	not reported	(4.6)*	60.3M	9.8 quarters	Q2 FY26 10-QJun 30, 2026
Sagimet Biosciences	166	not reported	(11)*	not reported	21.6 quarters	Q2 FY26 10-QJun 30, 2026
Atea Pharmaceuticals	77	not reported	(37)*	80.2M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Lifecore Biomedical	17	not reported	(2.2)*	37.9M	7.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.